Determinants of Diabetes Remission After Gastric Bypass Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-10-31

Study Completion Date

2019-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Longitudinal study of beta cell function up to 2 years after GBP surgery. Evaluation of the role of endogenous glucagon-like peptide-1 (GLP-1).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass

NCT01843855

Type 2 Diabetes Mellitus

COMPLETED EARLY_PHASE1

Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

NCT01803451

Post-bariatric Surgery

RECRUITING EARLY_PHASE1

To Define the Role of GLP-1 for Improving Glucose Homeostasis in Humans Following Gastric Bypass Surgery

NCT02204813

Bypass, Gastric Roux-en-Y Gastric Bypass Vertical Sleeve Gastrectomy +2 more

COMPLETED PHASE1

Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric Surgery

NCT02550145

Hypoglycemia

TERMINATED PHASE1

The Importance of GLP-1 in Post RYGB Improvement in Glycaemic Control Type 2 Diabetic Subjects

NCT01579981

Type 2 Diabetes

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The increased prevalence of obesity and type 2 diabetes (T2DM) has resulted in a surge in the number of patients seeking surgical weight loss. Gastric bypass surgery (GBP) results in 30-40% body weight loss with resolution of T2DM in 40-80% of cases. The mechanisms by which T2DM improves after GBP are unclear. Glycemic control occurs long before significant weight loss, suggesting that the nature of the procedure, rather than the weight loss, is responsible for the T2DM improvement. Recent data have singled out the role of the gut hormones known as incretins in diabetes improvement after GBP. The current proposal will study 1) whether the short and long term change in the gut hormone incretins after GBP results in improved insulin secretion in response to the administration of oral and IV glucose, in patients with diabetes undergoing GBP surgery; 2) the factors responsible for diabetes remission - or lack of - after GBP. The investigators wish to apply our finding to define better surgical outcome on diabetes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Exendin9

Longitudinal study of insulin secretion and sensitivity in patients with type 2 diabetes before and after gastric bypass surgery.

Group Type EXPERIMENTAL

Exendin9

Intervention Type DRUG

Dosed at 600 pmol/kg/min for 210 minutes.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Exendin9

Dosed at 600 pmol/kg/min for 210 minutes.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Exendin(9-39)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with a wide range of T2DM (duration, treatment modalities and control, in or not in remission) and scheduled for GBP surgery
* Blood pressure is under at least moderate control \<160/100 mmHg
* Patients can be on dyslipidemia medications but need fasting triglyceride \< 600 mg/dl
* Patients without recent (last 6 months) history of cardiovascular disease (CVD)
* BMI \> 35 and \< 55 kg/m2 prior to GBP surgery

Exclusion Criteria

* Active cancer
* Unstable angina
* Recent stroke
* Current therapy that may affect glucose metabolism such as glucocorticoids, HIV medications, etc
* Active infection
* Kidney failure
* Severe liver dysfunction
* Severe respiratory or cardiac failure
* History of allergic reaction to exendin 9-39
* History of pancreatitis, history of cholelithiasis, history of alcoholism
* Presence of high triglyceride levels (\>600 ng/dl)
* Pregnancy (a pregnancy test will be done prior to enrollment and prior to each procedure in all premenopausal women)

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No